CN111212644A - 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 - Google Patents

作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 Download PDF

Info

Publication number
CN111212644A
CN111212644A CN201880067060.1A CN201880067060A CN111212644A CN 111212644 A CN111212644 A CN 111212644A CN 201880067060 A CN201880067060 A CN 201880067060A CN 111212644 A CN111212644 A CN 111212644A
Authority
CN
China
Prior art keywords
amorphous solid
compound
solid dispersion
formula
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880067060.1A
Other languages
English (en)
Other versions
CN111212644B (zh
Inventor
吴予川
陈曦
黄少强
胡永韩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Sinoway Pharmaceutical Technology Co ltd
Original Assignee
Suzhou Sinovent Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Sinovent Pharmaceuticals Co Ltd filed Critical Suzhou Sinovent Pharmaceuticals Co Ltd
Publication of CN111212644A publication Critical patent/CN111212644A/zh
Application granted granted Critical
Publication of CN111212644B publication Critical patent/CN111212644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种如式(I)所示的新型5‑氨基吡唑甲酰胺化合物在非离子型聚合物中的无定型固体分散体。此外，本发明还公开了上述化合物在非离子型聚合物中的无定型固体分散体的制备方法以及包含上述化合物在非离子型聚合物中的无定型固体分散体的药物组合物及其用途。

Description

PCT国内申请，说明书已公开。

Claims (7)

  1. PCT国内申请，权利要求书已公开。
CN201880067060.1A 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 Active CN111212644B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017111049208 2017-11-10
CN201711104920 2017-11-10
PCT/CN2018/114658 WO2019091438A1 (zh) 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体

Publications (2)

Publication Number Publication Date
CN111212644A true CN111212644A (zh) 2020-05-29
CN111212644B CN111212644B (zh) 2021-01-15

Family

ID=66438751

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880067060.1A Active CN111212644B (zh) 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体

Country Status (2)

Country Link
CN (1) CN111212644B (zh)
WO (1) WO2019091438A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230062746A1 (en) * 2019-12-20 2023-03-02 Intervet Inc. A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2017198050A1 (zh) * 2016-05-16 2017-11-23 浙江予川医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001671A (es) * 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2017198050A1 (zh) * 2016-05-16 2017-11-23 浙江予川医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物

Also Published As

Publication number Publication date
CN111212644B (zh) 2021-01-15
WO2019091438A1 (zh) 2019-05-16

Similar Documents

Publication Publication Date Title
CA2971640C (en) Cot modulators and methods of use thereof
CN109952303B (zh) Tyk2抑制剂及其用途
CN107382973B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物
JP5490789B2 (ja) キナーゼ阻害剤としての新規なフェニルピラジノン
JP5259739B2 (ja) 新規ピリジノン及びピリダジノン
JP6751081B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
CN109415367A (zh) 用于治疗和预防乙型肝炎病毒感染的新的二氢吡咯并嘧啶类化合物
WO2017064156A1 (en) Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20110183974A1 (en) 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists
CN111153906B (zh) 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
EP2334683B1 (en) Saturated bicyclic heterocyclic derivatives as smo antagonists
KR20150054994A (ko) 브루톤 티로신 키나아제의 억제제
KR101707761B1 (ko) 브루톤 티로신 키나아제 억제제로서의 티아졸 유도체
CN111225912B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
CN111212644B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
KR20160145780A (ko) 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
CA2929785C (en) Inhibitors of bruton's tyrosine kinase
WO2010082044A1 (en) Unsaturated bicyclic heterocyclic derivatives as smo antagonists
CN111225669B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
EP4169904A1 (en) Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: Suzhou Sinoway Pharmaceutical Technology Co.,Ltd.

Address before: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee before: Suzhou Sinovent Pharmaceuticals Co.,Ltd.

CP01 Change in the name or title of a patent holder